-
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Baltimore
-
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Columbia
-
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Baltimore, Potomac, White Marsh
-
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
NCT06842186 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Maryland: Baltimore
-
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
NCT07656727 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Rockville
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· Maryland: Baltimore
-
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
NCT07639021 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Rockville
-
A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity
NCT07566390 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Maryland: Baltimore
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285 ·
Phase: Phase 3 ·
Ages: 8 Years to 18 Years ·
Sex: All (male and female)
· Maryland: Baltimore
-
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Rockville
-
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Baltimore, Bowie, Ft. Washington, Rockville
-
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
NCT07654374 ·
Phase: Phase 3 ·
Ages: 18 Years to 79 Years ·
Sex: All (male and female)
· Maryland: Silver Spring
-
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Columbia
-
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Baltimore, Hyattsville
-
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Bowie
-
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Columbia
-
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT07743450 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Bowie, Rockville
-
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT07743463 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Bowie, Rockville
-
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
NCT07575932 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Lutherville
-
A Study of Pitolisant in Patients With Prader-Willi Syndrome
NCT06366464 ·
Phase: Phase 3 ·
Ages: 6 Years and older ·
Sex: All (male and female)
· Maryland: Baltimore
-
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
NCT06864026 ·
Phase: Phase 4 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Cumberland, Hagerstown
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
NCT07511205 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Maryland: Brooklyn
-
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
NCT07013643 ·
Phase: Phase 1 ·
Ages: 35 Years to 75 Years ·
Sex: Female
· Maryland: Brooklyn
-
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
NCT06857942 ·
Phase: Phase 4 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Rockville
-
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
NCT07723833 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Maryland: Brooklyn
-
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
NCT07595549 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Baltimore
-
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
NCT07441252 ·
Phase: Phase 2 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· Maryland: Glen Burnie
-
Brain and Behavior Influences on Obesity Development From Infancy Through Childhood
NCT06861868 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 7 Years to 12 Years ·
Sex: All (male and female)
· Maryland: Baltimore
-
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
NCT01143454 ·
Phase: Not specified ·
Ages: 1 Year to 100 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Children s Growth and Behavior Study
NCT02390765 ·
Phase: Not specified ·
Ages: 8 Years to 100 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Diabetes and Heart Disease Risk in Blacks
NCT00001853 ·
Phase: Not specified ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Diet Order Effects of Low Fat vs. Low Carb Diets on Body Fat Change
NCT06325722 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 50 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Dinner Time for Obesity and Prediabetes
NCT05745441 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 50 Years ·
Sex: All (male and female)
· Maryland: Baltimore, Bethesda
-
Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate
NCT06044935 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
NCT07654361 ·
Phase: Phase 3 ·
Ages: 18 Years to 79 Years ·
Sex: All (male and female)
· Maryland: Silver Spring
-
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
NCT07284901 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Annapolis, Columbia
-
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Columbia
-
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
NCT06847399 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Baltimore
-
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects
NCT07166081 ·
Phase: Phase 1 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Maryland: Baltimore
-
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433 ·
Phase: Phase 3 ·
Ages: 45 Years to 99 Years ·
Sex: All (male and female)
· Maryland: Baltimore, Oxon Hill, Rockville
-
Evaluation of Children With Endocrine and Metabolic-Related Conditions
NCT02769975 ·
Phase: Not specified ·
Ages: 3 Months to 100 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Health Promotion With Targeted Exercise Intervention for Decreasing Fall Risk and Inactivity in Aging Veterans With Obesity and Signs of Sarcopenia
NCT07206368 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 55 Years and older ·
Sex: All (male and female)
· Maryland: Baltimore
-
Healthy for Two-Home Visiting (H42-HV): Health Coaching for Pregnant Women
NCT05619705 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Female
· Maryland: Baltimore
-
Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention
NCT01927783 ·
Phase: Not specified ·
Ages: 19 Years to 85 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Induction of Labor in Morbidly Obese Patients
NCT06199154 ·
Phase: Early Phase 1 ·
Ages: 18 Years and older ·
Sex: Female
· Maryland: Baltimore
-
MEHMO Natural History and Biomarkers
NCT06019182 ·
Phase: Not specified ·
Ages: 1 Week to 100 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459 ·
Phase: Phase 3 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· Maryland: Baltimore, Beltsville, Bowie
-
Mechanisms Underlying Individual Variations of Taste and Smell in Obesity
NCT04714892 ·
Phase: Not specified ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors
NCT07032545 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: No age limits stated ·
Sex: Female
· Maryland: Baltimore
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
NCT06273072 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Baltimore
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086 ·
Phase: Phase 3 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Maryland: Chevy Chase
-
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099 ·
Phase: Phase 3 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Maryland: Chevy Chase
-
Modifying Adiposity Through Behavioral Strategies to Improve COVID-19 Rehabilitation
NCT05880108 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: Up to 80 Years ·
Sex: All (male and female)
· Maryland: Baltimore
-
New Heart Imaging Techniques to Evaluate Possible Heart Disease
NCT01399385 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Nutrition Optimization and Community Upliftment for Postpartum Recovery
NCT06445530 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Female
· Maryland: Baltimore
-
Physical and Behavioral Traits of Overweight and Obese Adults
NCT00428987 ·
Phase: Not specified ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
NCT04228978 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Baltimore
-
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
NCT07446998 ·
Phase: Phase 2 ·
Ages: 65 Years to 100 Years ·
Sex: All (male and female)
· Maryland: Columbia
-
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
NCT03288207 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 21 Years to 75 Years ·
Sex: Female
· Maryland: Bethesda
-
The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists
NCT03049462 ·
Phase: Phase 1 ·
Ages: 18 Years to 40 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Trial of Food Is Medicine Approaches for Obesity Treatment in Adults With Food Insecurity
NCT07396805 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Baltimore
-
Understanding and Addressing Risks of Low Socioeconomic Status and Diabetes for Heart Failure
NCT06364644 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 30 Years to 70 Years ·
Sex: All (male and female)
· Maryland: Baltimore, Hagerstown
-
Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study
NCT06730113 ·
Phase: Not specified ·
Ages: 12 Years to 25 Years ·
Sex: All (male and female)
· Maryland: Bethesda